Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy

Imagem de Miniatura
Arquivos
art_DEBES_Hepatocellular_carcinoma_in_South_America_Evaluation_of_risk_2018.PDF (538.4 KB)
Citações na Scopus
61
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
DEBES, Jose D.
CHAN, Aaron J.
BALDERRAMO, Domingo
BALLERGA, Esteban Gonzalez
PRIETO, Jhon E.
TAPIAS, Monica
IDROVO, Victor
DAVALOS, Milagros B.
CAIRO, Fernando
Autor de Grupo de pesquisa
Citação
LIVER INTERNATIONAL, v.38, n.1, p.136-143, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background & AimsHepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. Most studies addressing the epidemiology of HCC originate from developed countries. This study reports the preliminary findings of a multinational approach to characterize HCC in South America. MethodsWe evaluated 1336 HCC patients seen at 14 centres in six South American countries using a retrospective study design with participating centres completing a template chart of patient characteristics. The diagnosis of HCC was made radiographically or histologically for all cases according to institutional standards. Methodology of surveillance for each centre was following AASLD or EASL recommendations. ResultsSixty-eight percent of individuals were male with a median age of 64years at time of diagnosis. The most common risk factor for HCC was hepatitis C infection (HCV, 48%), followed by alcoholic cirrhosis (22%), Hepatitis B infection (HBV, 14%) and NAFLD (9%). We found that among individuals with HBV-related HCC, 38% were diagnosed before age 50. The most commonly provided therapy was transarterial chemoembolization (35% of HCCs) with few individuals being considered for liver transplant (<20%). Only 47% of HCCs were diagnosed during surveillance, and there was no difference in age of diagnosis between those diagnosed incidentally vs by surveillance. Nonetheless, being diagnosed during surveillance was associated with improved overall survival (P=.01). ConclusionsOur study represents the largest cohort to date reporting characteristics and outcomes of HCC across South America. We found an important number of HCCs diagnosed outside of surveillance programmes, with associated increased mortality in those patients.
Palavras-chave
demographics, hepatocellular carcinoma, risk factors, South America
URI
https://observatorio.fm.usp.br/handle/OPI/24914
Referências
  1. Choo SP, 2016, CANCER-AM CANCER SOC, V122, P3430, DOI 10.1002/cncr.30237
  2. Cucchetti A, 2014, J HEPATOL, V61, P333, DOI 10.1016/j.jhep.2014.03.037
  3. Edenvik P, 2015, LIVER INT, V35, P1862, DOI 10.1111/liv.12764
  4. El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061
  5. Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
  6. Harris S, 2012, J CLIN ONCOL, V30, DOI 10.1200/jco.2012.30.4_suppl.174
  7. Kirk GD, 2005, ONCOGENE, V24, P5858, DOI 10.1038/sj.onc.1208732
  8. Kudo M, 2016, LIVER INT, V36, P1196, DOI 10.1111/liv.13096
  9. Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1
  10. Llovet JM, 2012, J HEPATOL, V56, P908
  11. Lok AS, 2009, GASTROENTEROLOGY, V136, P138, DOI 10.1053/j.gastro.2008.09.014
  12. Margini C, 2016, LIVER INT, V36, P317, DOI 10.1111/liv.13031
  13. McGlynn KA, 2015, CLIN LIVER DIS, V19, P223, DOI 10.1016/j.cld.2015.01.001
  14. MENDEZSANCHEZ N, 2014, ANN HEPATOL S1, V13, pS4
  15. Mourad A, 2014, HEPATOLOGY, V59, P1471, DOI 10.1002/hep.26944
  16. Nogueira JA, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-204
  17. Nordenstedt H, 2010, DIGEST LIVER DIS, V42, pS206, DOI 10.1016/S1590-8658(10)60507-5
  18. Park JW, 2015, LIVER INT, V35, P2155, DOI 10.1111/liv.12818
  19. Ryerson AB, 2016, CANCER-AM CANCER SOC, V122, P1312, DOI 10.1002/cncr.29936
  20. Salomao M, 2010, AM J SURG PATHOL, V34, P1630, DOI 10.1097/PAS.0b013e3181f31caa
  21. Sherman M, 2012, HEPATOLOGY, V56, P793, DOI 10.1002/hep.25869
  22. Singal AG, 2017, GASTROENTEROLOGY, V152, P608, DOI 10.1053/j.gastro.2016.10.042
  23. Singal AG, 2015, CLIN GASTROENTEROL H, V13, P2140, DOI 10.1016/j.cgh.2015.08.014
  24. Tholey DM, 2015, GASTROENTEROL CLIN N, V44, P761, DOI 10.1016/j.gtc.2015.07.005
  25. Turner PC, 2002, J GASTROEN HEPATOL, V17, pS441, DOI 10.1046/j.1440-1746.17.s4.7.x
  26. Venook AP, 2010, ONCOLOGIST, V15, P5, DOI 10.1634/theoncologist.2010-S4-05
  27. Wallace MC, 2015, EXPERT REV GASTROENT, V9, P765, DOI 10.1586/17474124.2015.1028363
  28. Yang JD, 2015, AM J GASTROENTEROL, V110, P1629, DOI 10.1038/ajg.2015.289
  29. Yang YD, 2016, LANCET GASTROENTEROL, V2, P103
  30. Younossi ZM, 2016, HEPATOLOGY, V64, P73, DOI 10.1002/hep.28431

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - ODS/03